Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Inverness Medical Innovation - IMA -- Ignore unavailable to you. Want to Upgrade?

To: Crossy who wrote (3)	1/28/2003 6:55:58 AM
From: Crossy	Read Replies (1) \| Respond to of 40

Inverness Medical Innovations, Inc. Updates on Voluntary Conversions of Series A Convertible Preferred Stock Waltham, MA– September 16, 2002 – Inverness Medical Innovations, Inc. (AMEX: IMA), a leading provider of women’s health and nutritional products and developer of advanced medical device technologies, announced today that it has received commitments from preferred shareholders to convert at least 1,723,180 shares of the Company’s Series A Convertible Preferred Stock into shares of common stock. It is anticipated that the conversions, which are subject to, and a condition of, the closing of a financing transaction, will occur prior to the closing of the Company’s pending acquisition of MedPointe’s Wampole Laboratories unit. The Series A Preferred Stock will be converted without additional consideration in accordance with the preferred stock’s voluntary conversion provisions. The preferred shareholders who have committed to convert hold approximately 83.4% of the total shares of Series A Convertible Preferred Stock currently outstanding. The Company’s Series A Convertible Preferred Stock accrues dividends while the Company’s common stock remains below $15 per share. For more information about Inverness Medical Innovations, please visit our website at www.invernessmedical.com.